Form 8-K - Current report:
SEC Accession No. 0001193125-25-266866
Filing Date
2025-11-05
Accepted
2025-11-05 16:03:36
Documents
14
Period of Report
2025-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aclx-20251105.htm   iXBRL 8-K 47894
2 EX-99.1 aclx-ex99_1.htm EX-99.1 19777
3 GRAPHIC img167846775_0.jpg GRAPHIC 13072
4 GRAPHIC img167846775_1.jpg GRAPHIC 111852
5 GRAPHIC img167846775_2.jpg GRAPHIC 409788
  Complete submission text file 0001193125-25-266866.txt   913370

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aclx-20251105.xsd EX-101.SCH 25008
16 EXTRACTED XBRL INSTANCE DOCUMENT aclx-20251105_htm.xml XML 4744
Mailing Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065
Business Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065 240-327-0603
Arcellx, Inc. (Filer) CIK: 0001786205 (see all company filings)

EIN.: 472855917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41259 | Film No.: 251453800
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)